Age-related muscle weakness affects millions of older adults, yet no approved drugs exist to combat this debilitating condition. A surprising therapeutic avenue may emerge from blocking rather than activating a hormone pathway traditionally associated with muscle growth. Male mice genetically engineered to lack ghrelin receptors maintained superior muscle strength, endurance, and fatigue resistance as they aged compared to normal mice. The protective effect occurred without preserving muscle mass itself, suggesting the quality rather than quantity of muscle tissue improved. A pharmacological compound called PF-5190457 that blocks these same receptors replicated the benefits when given to normal aging mice. The mechanism appears to center on mitochondrial health within muscle cells. Aged mice lacking ghrelin receptors showed enhanced levels of PGC-1α, a master regulator of mitochondrial creation, along with improved cellular cleanup processes that remove damaged mitochondria. This finding challenges conventional wisdom about ghrelin, known primarily as the hunger hormone that stimulates appetite and growth hormone release. While ghrelin typically promotes short-term muscle building, chronic activation may actually impair long-term muscle function through mitochondrial dysfunction. The research provides compelling preclinical evidence for a counterintuitive approach to sarcopenia treatment. However, the male-only study design limits generalizability, and translating mouse longevity research to humans remains notoriously challenging. Still, this represents one of the first mechanistically-grounded pharmacological targets for age-related muscle decline, potentially opening new therapeutic pathways for maintaining physical independence in older adults.